Antibody drug conjugates (ADCs) having enzymatically cleavable groups

US11660351B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Hans-Georg Lerchen · Leverkusen, DE
• Anne-Sophie REBSTOCK · Écully, FR
• Beatrix Stelte-Ludwig · Wülfrath, DE
• Dennis KIRCHHOFF · Berlin, DE
• Lisa DIETZ · Wuppertal, DE
• Christoph MAHLERT · Wuppertal, DE
• Simone Greven · Dormagen, DE
• Stephan MÄRSCH · Cologne, DE
• Sandra BERNDT · Hohen Neuendorf, DE
• Anette SOMMER · Berlin, DE
• Stefanie HAMMER · Berlin, DE

Key dates

• Filing date: Dec 14, 2017
• Grant date: May 30, 2023
• Expiry date: Mar 8, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/24
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.